
FDA approves Bimzelx for hidradenitis suppurativa
The U.S. Food and Drug Administration has approved UCB’s Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate-to-severe hidradenitis suppurativa.This article was originally published on MedicalXpress.com